Could This Experimental Therapy be a Breakthrough for Genetic Amyotrophic Lateral Sclerosis?
NeuPaddy / Pixabay

Could This Experimental Therapy be a Breakthrough for Genetic Amyotrophic Lateral Sclerosis?

According to a story from fox43.com, an experimental therapy for the genetic form of amyotrophic lateral sclerosis (ALS) has been termed "game changing." A study that will soon be presented…

Continue Reading Could This Experimental Therapy be a Breakthrough for Genetic Amyotrophic Lateral Sclerosis?

Vascular Ehlers-Danlos Syndrome Patient Data Released Following Study

According to a story from globenewswire.com, the pharmaceutical company Acer Therapeutics recently announced the release of data from a long-term observational study of patients with vascular Ehlers-Danlos syndrome (vEDS). All…

Continue Reading Vascular Ehlers-Danlos Syndrome Patient Data Released Following Study

Researchers Believe Lithium May be Key to Developing a Drug for Limb Girdle Muscular Dystrophy

The News Hub at Washington State University recently carried an article describing initial success by researchers towards developing a drug for a rare form of muscular dystrophy. Several thousand people…

Continue Reading Researchers Believe Lithium May be Key to Developing a Drug for Limb Girdle Muscular Dystrophy
Baby’s Death in Spinal Muscular Atrophy Gene Therapy Trial Could be Linked to Treatment, Company Says
geralt / Pixabay

Baby’s Death in Spinal Muscular Atrophy Gene Therapy Trial Could be Linked to Treatment, Company Says

According to a story from BNN Bloomberg, Novartis AG, a drug company that is nearing the completion of the development of a potentially groundbreaking new gene therapy for spinal muscular…

Continue Reading Baby’s Death in Spinal Muscular Atrophy Gene Therapy Trial Could be Linked to Treatment, Company Says
Over 50% of Ankylosing Spondylitis Patients Relapse After Halting Infliximab, Study Claims
mohamed_hassan / Pixabay

Over 50% of Ankylosing Spondylitis Patients Relapse After Halting Infliximab, Study Claims

According to a story from Healio, a recent study has found that 58 percent of patients with the inflammatory disease ankylosing spondylitis will experience relapse within one year after stopping…

Continue Reading Over 50% of Ankylosing Spondylitis Patients Relapse After Halting Infliximab, Study Claims
Analysis of Hepatocellular Carcinoma Trial Presented at 2019 Gastrointestinal Cancers Symposium
MariSmithPix / Pixabay

Analysis of Hepatocellular Carcinoma Trial Presented at 2019 Gastrointestinal Cancers Symposium

According to a story from finanzen.ch, the pharmaceutical company Eisai, Inc. announced that that company presented a total of four abstracts which were related to a Phase 3 clinical trial…

Continue Reading Analysis of Hepatocellular Carcinoma Trial Presented at 2019 Gastrointestinal Cancers Symposium
As UK Cystic Fibrosis Patients Push for Drug Coverage, a Girl That Died too Soon Becomes the Face of the Campaign
Walkerssk / Pixabay

As UK Cystic Fibrosis Patients Push for Drug Coverage, a Girl That Died too Soon Becomes the Face of the Campaign

According to a story from express.co.uk, Elle Morris was only 11 years old when she died from a severe lung infection. Elle was born with cystic fibrosis, a serious genetic…

Continue Reading As UK Cystic Fibrosis Patients Push for Drug Coverage, a Girl That Died too Soon Becomes the Face of the Campaign

Early Trial Data Suggests Safety and Potential Efficacy of Experimental Drug in Treating Advanced Hepatocellular Carcinoma

According to a story from BioPortfolio, the biotechnology company Tiziana Life Sciences plc recently announced encouraging results from an interim safety review of the company's Phase 2a clinical trial. This…

Continue Reading Early Trial Data Suggests Safety and Potential Efficacy of Experimental Drug in Treating Advanced Hepatocellular Carcinoma
Recent Study Indicates That SPINRAZA can Benefit Patients with Late-Onset Spinal Muscular Atrophy
Pexels / Pixabay

Recent Study Indicates That SPINRAZA can Benefit Patients with Late-Onset Spinal Muscular Atrophy

According to a story from globenewswire.com, the biotechnology company Biogen recently released data from an open label study that was testing the company's spinal muscular atrophy drug nusinersen (marketed as…

Continue Reading Recent Study Indicates That SPINRAZA can Benefit Patients with Late-Onset Spinal Muscular Atrophy

New Drug Under Review by the FDA to Treat the Most Lethal Form of Spinal Muscular Atrophy

  According to an article in Biospace, the FDA is currently reviewing data from the Phase III STRIVE clinical trial for possible approval of Zolgensma as gene therapy for spinal…

Continue Reading New Drug Under Review by the FDA to Treat the Most Lethal Form of Spinal Muscular Atrophy

Fulcrum Therapeutics Acquires Experimental Facioscapulohumeral Muscular Dystrophy Drug

According to a press release from Massachusetts-based biotech company Fulcrum Therapeutics, the company has successfully secured global commercialization rights of GlaxoSmithKline-developed experimental facioscapulohumeral muscular dystrophy (FSHD) drug losmapimod. Losmapimod, an…

Continue Reading Fulcrum Therapeutics Acquires Experimental Facioscapulohumeral Muscular Dystrophy Drug

Experimental Treatment for Neuromyelitis Optica Earns Breakthrough Therapy Designation

According to a story from BioSpace, the biotechnology company Viela Bio recently announced that the US Food and Drug Administration (FDA) has awarded an experimental therapy in development by the…

Continue Reading Experimental Treatment for Neuromyelitis Optica Earns Breakthrough Therapy Designation
New Sensor Technology Can Detect Medication Response Automatically for Parkinson’s Disease Patients
shixugang / Pixabay

New Sensor Technology Can Detect Medication Response Automatically for Parkinson’s Disease Patients

According to a story from EurekAlert!, effective management of Parkinson's disease can be a serious challenge. Part of the reason that the management of the illness is so difficult is…

Continue Reading New Sensor Technology Can Detect Medication Response Automatically for Parkinson’s Disease Patients

Companies Announce Collaboration to Develop Gene Therapy for Recessive Dystrophic Epidermolysis Bullosa

According to a story from globenewswire.com, the gene therapy company Fibrocell Science, Inc. and the biopharmaceutical company Castle Creek Pharmaceuticals have recently announced a collaboration between the two companies. The…

Continue Reading Companies Announce Collaboration to Develop Gene Therapy for Recessive Dystrophic Epidermolysis Bullosa